Analysis of third-line H. pylori eradication therapy with sitafloxacin

Analysis of third-line H. pylori eradication therapy with sitafloxacin - Analysis of H. pylori eradication with sitafloxacin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001902

Enrollment

Registered

2009-04-24

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with H. pylori eradication failure after first- and second-line therapy

Interventions

H. pylori eradication therapy with sitafloxacin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Peptic ulcer patients with H. pylori eradication failure after first and second-line therapy

Exclusion criteria

Exclusion criteria: penicillin or quinolone allergy rabeprazole allergy severe liver or renal dysfunction pregnancy or suckling cases with unsuitable determined by doctors

Design outcomes

Primary

Measure	Time frame
Eradication rate of H. pylori infection by the regimen including sitafloxacin	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026